ArticleBMC infectious diseases2026
Borrelia valaisiana - a candidate human pathogen? Insights from the tick-borne diseases STING study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBorrelia (B.) valaisiana is a tick-borne spirochete within the Borrelia burgdorferi sensu lato complex. In Sweden, it occurs in Ixodes ricinus ticks, but its role as a human pathogen remains uncertain. In the Tick-Borne Diseases STING study conducted during 2007-2015, adult participants from Sweden and the Åland Islands, Finland, provided ticks, blood samples for serological analyses, and questionnaires at inclusion and at a 3-month follow-up. Medical records were reviewed for those seeking care. Ticks were characterised, feeding duration assessed, and pathogens detected by real-time PCR. During 2008-2009, B. valaisiana was identified by PCR in 1.6% (34/2,154) of the ticks. Since its significance as a human pathogen is unclear, we chose to examine this tick-bitten cohort in greater detail. Accordingly, the objective of the study was to assess whether participants bitten by B. valaisiana-positive ticks developed Borrelia-specific antibodies and/or symptoms suggestive of infection. MATERIALS AND
methodsParticipants bitten by B. valaisiana-positive ticks (VPOS, n = 33; one bitten twice) were compared with an age- and sex-matched group bitten by Borrelia-negative ticks (VNEG, n = 67). Borrelia-specific IgG was analysed in paired blood samples.
resultsMedian age in VPOS was 67 years; 58% were women. Seroconversion for Borrelia-specific IgG occurred significantly more often in VPOS than VNEG (p = 0.03). Common symptoms in VPOS included neck pain, myalgia/arthralgia, numbness, and headache, but none sought medical care. No significant difference in symptom occurrence was observed between groups.
conclusionTick bites involving B. valaisiana were associated with higher Borrelia antibody seroconversion, without significant symptom associations or need for medical intervention. The results of this study provide new insights into the potential human impact of B. valaisiana.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.